Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Other Accumulated Expenses (2023 - 2025)

Compass Therapeutics' Other Accumulated Expenses history spans 3 years, with the latest figure at $484000.0 for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 22.06% year-over-year to $484000.0; the TTM value through Dec 2025 reached $484000.0, down 22.06%, while the annual FY2025 figure was $484000.0, 22.06% down from the prior year.
  • Other Accumulated Expenses for Q4 2025 was $484000.0 at Compass Therapeutics, up from $141000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $621000.0 in Q4 2024 and bottomed at $137000.0 in Q1 2023.
  • The 3-year median for Other Accumulated Expenses is $277500.0 (2024), against an average of $306916.7.
  • The largest YoY upside for Other Accumulated Expenses was 158.75% in 2024 against a maximum downside of 57.29% in 2024.
  • A 3-year view of Other Accumulated Expenses shows it stood at $240000.0 in 2023, then soared by 158.75% to $621000.0 in 2024, then fell by 22.06% to $484000.0 in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Other Accumulated Expenses are $484000.0 (Q4 2025), $141000.0 (Q3 2025), and $384000.0 (Q2 2025).